QUINOLIN-4-YL DERIVATIVES I

The invention relates to compounds of formula wherein R1 is hydrogen, lower alkyl, lower alkoxy, hydroxy, amino, nitro, cyano, lower alkyl-amino, di-lower alkyl-amino or halogen; R2 is phenyl, optionally substituted by lower alkyl, lower alkoxy, halogen, trifluoromethyl, amino, lower alkyl-amino or di-lower alkyl-amino, 2,3- dihydro-benzofuran-5-yl, chroman-6-yl, naphthalen-2-yl, indan-5-yl, lower alkenyl-phenyl, 5,6,7,8-tetrahydro-naphthalenyl, 2,3-dihydro-isoindol-2-yl, 1,2,3,4-tetrahydro-naphthalenyl, benzofuran-2-yl, benzo[b]thiophen-2-yl, lower alkyl-phenyl, 3,4-dihydro-1H-isoquinolin-2-yl or thiophen-3-yl; R3 and R4 are independently from each other hydrogen or lower alkyl; R5 is hydrogen, lower alkyl, -CH2OH or ûCH2NR6R7; R6 and R7 are independently from each other hydrogen, lower alkyl, -(CH2)n-phenyl, cycloalkyl, -(CH2)m-morpholinyl or form together with the N- atom a saturated ring with 4-6C-atoms; n is 0-3; m is 2 or 3; X is ûNR8- or -0-; or X and R5 are together >N(CH2)2-; or X and R3 are together >N(CH2)3-; and R8 is hydrogen or lower alkyl; and to pharmaceutically acceptable acid addition salts thereof, with the exception of the following compounds (6-chloro-2-phenyl-4-quinolinyl)-(+)-2-aminobutanol; (6-methyl-2-phenyl-4-quinolinyl)-(+)-2-aminobutanol; (6-methoxy-2-phenyl-4-quinolinyl)-(+)-2-aminobutanol; and (8-methoxy-2-phenyl-4-quinolinyl)-(+)-2-aminobutanol, which maybe used for the treatment of diseases, which relate to the NMDA receptor specific blockers.